Bafna Pharmaceuticals Share Price

Bafna Pharma.

CMP as on 16-May-22 15:29

₹ 127.60
1.65 1.31%

Open

₹ 125.95

Turnover (lac)

₹ 1

Prev. Close

₹ 125.95

Day's Vol (shares)

₹ 520

Day's Range (₹)

₹ 125.95
₹ 129.45

CMP as on16-May-22 15:29

₹ 127.00
-1.6 -1.24%

Open

₹ 129.80

Turnover (lac)

₹ 4

Prev. Close

₹ 128.60

Day's Vol (shares)

₹ 289

Day's Range

₹ 125.10
₹ 129.80

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 17-Mar-2022 - -
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/03/2022 inter alia to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday 21st day of March 2022 online through zoom video conferencing at 11.00 A.M to inter alia consider resignation and appointment of Company Secretary (KMP) of the Company and any other business with the permission of chair. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of said Regulations, this is to inform you that the Board of Directors in its meeting held today i.e. 21st March 2022 , considered and approved the appointment of Mrs. Roopa Ravikumar (Membership No: F11282) as Company Secretary & Compliance officer of the Company w.e.f 22nd March 2022. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of said Regulations, this is to inform you that the Board of Directors in its meeting held today i.e. 21st March 2022 , considered and approved the following: 1. Resignation by Mr. Jitendra Kumar Pal from the post of Company Secretary & Compliance officer of the Company due to personal reasons with effect from closure of business hours on 21st March 2022. 2.. Appointment of Mrs. Roopa Ravikumar (Membership No: F11282) as Company Secretary & Compliance officer of the Company w.e.f 22nd March 2022 (As Per BSE Announcement dated on 21.03.2022)
Board Meeting - 01-Feb-2022 - -
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 inter alia to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday 10th February 2022 to inter alia consider and adopt un-audited financial results for the quarter and nine months ended 31st December 2021 and any other business with the permission of the Chair. outcome of board meeting (As Per BSE Announcement Dated on 10/02/2022)
Board Meeting - 03-Nov-2021 - -
Quarterly Results Bafna Pharmaceuticals Ltd has informed BSE regarding Outcome of Board Meeting held on November 12 2021. Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (Listing Regulations) as amended, this is to inform you that the Board of Directors (Board) of the Company, had at its meeting held today i.e. Friday, November 12, 2021, the Board has decided the following matters: 1. Approved the un - audited financial results of the Company for the quarter /half year ended September 30, 2021. Please find attached Limited Review Report from the Statutory Auditor. 2. Statutory Auditors comments along with Managements Reply: 3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. 3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. The Board has constituted a Rights Issue Committee of Directors for the above purpose and has authorised the Committee to determine the terms of the Rights Issue including the quantum of issue, rights entitlement ratio, issue price, issue size, book closure or record date, entitlement timing of the issue, appointment of intermediaries, etc., in consultation with the Lead Manager to the Right Issue and to decide all other matters relating to the Right Issue. Such details shall be informed and/or announced in due course as and when decided or required, as per applicable statutory provisions and depending upon the market conditions. The above proposal to issue of shares shall be subject to necessary approvals, confirmations and consents as may be necessary and in compliance with applicable law including Bafna Pharmaceuticals Ltd has informed BSE regarding Outcome of Board Meeting held on November 12, 2021. (As Per BSE Announcement Dated on 11/12/2021 9:02:22 AM)
Board Meeting - 15-Sep-2021 - -
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/09/2021 inter alia to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday 16th Sep 2021 online through video conferencing to inter alia consider the proposal of availing working capital / term loan facility for expansion program and any other business with the permission of the Chair The Board of Directors of the Company at their meeting held on today i.e 16th September 2021 inter-alia transacted the following business.:- 1. Availing of working capital / Term Loan facility upto Rupees Thirty Crores from ICICI Bank. 2. Opening of Cash Credit Account with ICICI bank. for expansion program. The Board Meeting commenced at 11.00 A.M and concluded at 12.00 Noon. (As Per BSE Announcement Dated on 16.09.2021)
Board Meeting - 27-Jul-2021 - -
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2021 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 05th August 2021 online through video conferencing, to inter alia consider and adopt un-audited financial results for the first quarter ending 30th June 2021 and any other business with the permission of the Chair. Further in accordance with the Code of Conduct for prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in securities of the Company shall remain closed until 48 hours after the financial results approved at the meeting are made public. The Board of Directors of the Company at their meeting held on today inter-alia transacted the following business.:- 1. UN-AUDITED FINANCIAL RESULT Approval of un-audited financial results of the Company for the quarter ending 30th June 2021. Please find attached Limited Review Report from the statutory auditor of the Company M/s. R. Sathyanarayanan & Co. (As per BSE Announcement Dated on 5/8/2021)
Board Meeting - 14-Jun-2021 - -
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/06/2021 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday, 25th June 2021 to inter alia consider and adopt audited financial results for the quarter / year ended 31st March 2021 and any other business with the permission of the Chair. 1. AUDITED FINANCIAL RESULT Approval of audited financial results of the Company for the quarter and year ending 31st March 2021. M/s. R. Sathyanarayanan & Co, Chartered Accountant, the Statutory Auditors of the Company have issued Audit Report with modified opinion along with Statement on impact of Modified opinion thereon. Please find enclosed Audited Financial Results, Audit Report, Statement of Assets & Liabilities and Statement on Impact of Modified Opinion thereon for the year ended on March 31, 2021. 2. ANNUAL GENERAL MEETING The 26th Annual General Meeting of the members of the Company is scheduled to be held on Saturday the 14th August 2021. (As Per BSE Announcement dated on 25.06.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity